Skip links

Takhzyro® (lanadelumab-flyo)

Full Name Takhzyro® (lanadelumab-flyo)
Drug Takhzyro
Manufacturer Takeda Pharmaceuticals U.S.A., Inc.
Route of Administration Subcutaneous
Site of Care Home
Approved Indication Prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older
Disease Hereditary Angioedema (HAE)
Therapeutic Area Allergy & Immunology
Enrollment Form Link Enrollment Form
Phone Number 800-356-4252
Fax Number 847-631-6918
Product Website takhzyro.com